Octagon Capital Advisors’s Mirum Pharmaceuticals MIRM Stock Holding History

Octagon Capital Advisors’s Portfolio MIRM Stock Details MIRM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$39.7M	Hold	338,900	–	–	3.57%	9
2026 Q1	$31.3M	Buy	+338,900	New	+$31.9M	3.46%	9
2024 Q1	–	Sell	-25,000	Closed	-$738K	–	61
2023 Q4	$738K	Buy	+25,000	New	+$757K	0.12%	31
2023 Q1	–	Sell	-100,000	Closed	-$1.95M	–	39
2022 Q4	$1.95M	Hold	100,000	–	–	0.3%	25
2022 Q3	$2.1M	Buy	+100,000	New	+$2.41M	0.36%	30

Other funds holding MIRM

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Octagon Capital Advisors's MIRM Position: Q2 2026 in Review

Octagon Capital Advisors held its Mirum Pharmaceuticals (MIRM) position steady in Q2 2026 at 338,900 shares worth $39.7M. The position accounts for 3.57% of the portfolio, ranked #9.

Octagon Capital Advisors first reported a position in MIRM in Q3 2022 and has held it in 5 quarters since. 327 funds tracked by Wall St. Rank hold MIRM as of Q2 2026.

Octagon Capital Advisors held 338,900 shares of Mirum Pharmaceuticals worth $39.7M as of Q2 2026.
Octagon Capital Advisors left its Mirum Pharmaceuticals share count unchanged in Q2 2026.
Mirum Pharmaceuticals made up 3.57% of Octagon Capital Advisors's portfolio in Q2 2026, its #9 holding.
Octagon Capital Advisors first reported a position in Mirum Pharmaceuticals in Q3 2022 and has held it in 5 quarters since.
327 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q2 2026.

Based on Octagon Capital Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.